{
    "clinical_study": {
        "@rank": "107608", 
        "arm_group": [
            {
                "arm_group_label": "Pimasertib (once daily) plus SAR245409 and Pimasertib placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Pimasertib (twice daily) plus SAR245409 placebo", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double blind, randomized, placebo-controlled, 2-arm,  Phase 2 trial  investigating\n       the  efficacy  and safety  of combination therapy of pimasertib  plus SAR245409 and\n      pimasertib placebo administered once per day compared to pimasertib administered twice per\n      day plus SAR245409  placebo  administered  once  per  day in subjects with previously\n      treated unresectable low-grade  ovarian  cancer."
        }, 
        "brief_title": "Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The female subject has a diagnosis of one of the following: a) low-grade serous\n             ovarian or peritoneal carcinoma, or grade 1 serous ovarian or peritoneal carcinoma or\n             well-differentiated serous ovarian or peritoneal carcinoma or b) serous borderline\n             ovarian or peritoneal tumor, ovarian or peritoneal tumor of low-malignant potential,\n             ovarian or peritoneal atypical proliferative serous tumor that recurs as low grade\n             serous carcinoma or has invasive peritoneal implants.\n\n          -  The subject had at least one prior line of systemic therapy and has a tumor, which is\n             not amenable to potentially curative surgical resection.\n\n          -  The subject has measurable disease by Response Evaluation Criteria in Solid Tumors\n             (RECIST) v1.1.\n\n          -  The subject is at least 18 years old.\n\n          -  The subject has read and understood the written informed consent form (ICF) and is\n             willing and able to give informed consent, fully understands the requirements of the\n             trial and is willing to comply with all trial visits and assessments, including\n             completion of patient-reported measures. Consent must be given before any trial\n             related activities.\n\n          -  Subjects of childbearing potential must have a negative serum pregnancy test at the\n             screening visit.\n\n          -  Subjects of childbearing potential must be willing to avoid pregnancy by using an\n             adequate method of contraception for 2 weeks prior to screening, during and at least\n             4 weeks after the last dose of trial medication.\n\n          -  Other protocol defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  The subject has previously been treated with a PI3K inhibitor and taken off treatment\n             due to treatment related AEs.\n\n          -  The subject has been previously treated with a Mitogen-activated\n             protein/extracellular signal-regulated kinase (MEK) inhibitor.\n\n          -  The subject has received chemotherapy, immunotherapy, hormonal therapy, biologic\n             therapy, or any other anti-cancer therapy within 28 days or within 5 times the half\n             life of a relevant agent prior to day 1 of trial drug treatment, whichever is\n             shorter, or has been treated with nitrosoureas or mitomycin C within the last 6\n             weeks.\n\n          -  The subject has not recovered from toxicity due to prior therapy to Baseline level or\n             National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0\n             (NCI CTCAE v4.0) Grade 1 or less (except alopecia).\n\n          -  The subject has poor organ and marrow function as defined in the protocol.\n\n          -  The subject has creatine phosphokinase (CPK) elevation NCI CTCAE grade >=2, and/or a\n             previous history of myositis or rhabdomyolysis.\n\n          -  The subject has difficulty swallowing, malabsorption or other chronic\n             gastrointestinal disease or conditions that may hamper compliance and/or absorption\n             of the trial drug.\n\n          -  The subject has a history of delayed healing/open wounds or diabetic ulcers.\n\n          -  The subject has a history of congestive heart failure, unstable angina, myocardial\n             infarction, cardiac conduction abnormalities including corrected QT interval\n             prolongation of > 480ms or a pacemaker, clinically relevant impaired cardiovascular\n             function (New York Heart Association (NYHA) class III/IV) or stroke within 3 months\n             prior to enrollment.\n\n          -  The subject has a history of retinal degenerative disease (hereditary retinal\n             degeneration or age-related macular degeneration), uveitis or retinal vein occlusion\n             (RVO), or has other relevant abnormalities identified on screening opthalmologic\n             examination, which may increase the risk of serous retinal detachment (SRD) or RVO.\n\n          -  The subject has a history of uncontrolled intercurrent illness including but not\n             limited to an active infection, hypertension, or uncontrolled diabetes (e.g.\n             glycosylated hemoglobin >= 8%) that would limit compliance with treatment\n             requirements.\n\n          -  Other protocol defined exclusion criteria may apply."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936363", 
            "org_study_id": "EMR 200066_012", 
            "secondary_id": "2013-000902-40"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pimasertib (once daily) plus SAR245409 and Pimasertib placebo", 
                "description": "Pimasertib will be administered as oral capsule at a dose of 60 milligram (mg) once daily  until  disease progression,  death, intolerable  toxicity or withdrawal of informed consent, whichever comes first.", 
                "intervention_name": "Pimasertib once daily", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pimasertib (once daily) plus SAR245409 and Pimasertib placebo", 
                "description": "Placebo matching Pimasertib will be administered once daily in evening until disease progression,  death,  intolerable  toxicity or withdrawal of informed consent, whichever comes first.", 
                "intervention_name": "Pimasertib placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pimasertib (twice daily) plus SAR245409 placebo", 
                "description": "Placebo matching SAR245409 will be administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.", 
                "intervention_name": "SAR245409  placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pimasertib (once daily) plus SAR245409 and Pimasertib placebo", 
                "description": "SAR245409 will be administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.", 
                "intervention_name": "SAR245409", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pimasertib (twice daily) plus SAR245409 placebo", 
                "description": "Pimasertib will be administered as oral capsule at a dose of 60 milligram (mg)  twice daily until  disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.", 
                "intervention_name": "Pimasertib twice daily", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ovarian Cancer", 
            "Pimasertib", 
            "Placebo", 
            "SAR245409"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "for US Recruiting Sites", 
                    "phone": "888-275-7376"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockland", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Please Contact U.S. Medical Information Located in"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "service@merckgroup.com", 
                    "last_name": "for EU Recruiting Sites", 
                    "phone": "+49-6151-72-5200"
                }, 
                "facility": {
                    "address": {
                        "city": "Darmstadt", 
                        "country": "Germany"
                    }, 
                    "name": "Please contact the Merck KGaA Communication Center located in"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer", 
        "overall_contact": {
            "last_name": "US Medical Information", 
            "phone": "888-275-7376"
        }, 
        "overall_contact_backup": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49-6151-72-5200"
        }, 
        "overall_official": {
            "affiliation": "Merck KGaA", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Objective tumor response will be measured from baseline until disease progression or death assessed every 8 weeks up to week 32, and thereafter every 12 weeks up to 2.5 years", 
            "measure": "Objective tumor response defined as complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1) as determined by the investigator", 
            "safety_issue": "No", 
            "time_frame": "up to 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936363"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from randomisation to the first documentation of objective disease progression according to RECIST v.1.1 as determined by the Investigator or death, whichever comes first. Death will be considered as a Progression-free survival (PFS) event only if it is reported within 12 weeks after the last tumor assessment without progression.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Time from randomization until first observation of progressive disease or death, when death occurs within 12 weeks of the last tumor assessment (whichever comes first), up to 30 days after last treatment"
            }, 
            {
                "description": "Disease control defined as the proportion of subjects with stable disease (SD) for at least 16 weeks, PR or CR according to RECIST v.1.1", 
                "measure": "Percentage of subjects with disease control according to RECIST v.1.1", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 8, 16, 24 and 32, and thereafter every 12 weeks up to 30 days after last treatment"
            }, 
            {
                "measure": "Overall survival time", 
                "safety_issue": "No", 
                "time_frame": "Time from randomization to death up to 12 months after last subject randomized"
            }, 
            {
                "description": "The QLQ-C30 is a 30-item questionnaire comprising of five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea/vomiting), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and a global QoL scale summarized from two 7-point scales (overall QoL and overall general health)", 
                "measure": "Health Related Quality of Life (HrQoL) assessed using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) Version 3.0", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29, and Week 8, 16, 24 and 32, and thereafter every 12 weeks up to 30 days after last treatment"
            }, 
            {
                "description": "The ovarian cancer module EORTC QLQ-OV28 assesses disease and treatment-related symptoms of ovarian cancer. The 28-item module comprises of 6 symptom scales (abdominal/gastrointestinal symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal symptoms, body image, attitude to disease and treatment), and sexual functioning. Both measures have been developed and validated in cross-cultural settings, exhibit good psychometric properties, and take between 10-15 minutes to complete", 
                "measure": "HrQoL assessed using EORTC QLQ-C30 Version 3.0 - ovarian-specific module QLQ-OV28", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29, and Week 8, 16, 24 and 32, and thereafter every 12 weeks up to 30 days after last treatment"
            }, 
            {
                "description": "TEAEs, SAEs and AEs will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0. An Adverse Event (AE) is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. Treatment-emergent adverse events are events from first dose of study drug that were absent before treatment or that worsened relative to pretreatment state.", 
                "measure": "Number of Subjects with Treatment Emergent Adverse Events (TEAEs), Adverse Events (AEs) of special interest, Serious Adverse Events (SAEs), discontinuation of treatment due to TEAEs, death", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 30 days after last treatment"
            }, 
            {
                "measure": "Maximum Plasma Concentration (Cmax) After Dose of pimasertib and SAR245409", 
                "safety_issue": "No", 
                "time_frame": "pre-dosing to 0.5, 1.5, 4.5 and 8 hours after the morning dose at day 15, 29, 43"
            }, 
            {
                "measure": "Area under the curve (AUC) After Dose of pimasertib and SAR245409", 
                "safety_issue": "No", 
                "time_frame": "pre-dosing to 0.5, 1.5, 4.5 and 8 hours after the morning dose at day 15, 29, 43"
            }, 
            {
                "measure": "Molecular Alterations in MAPK and/or PI3K signaling pathway components/modulators in tumor tissue and blood", 
                "safety_issue": "No", 
                "time_frame": "Screening visit (day -28 to 1)"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}